Hengrui Pharma's Adebrelimab Injection Gains Approval for Additional NSCLC Perioperative Indication

Stock News06-25 20:59

Hengrui Pharma has announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., recently received notification from the National Medical Products Administration. The notification approves the addition of a perioperative indication for non-small cell lung cancer (NSCLC) for the company's Adebrelimab injection.

This marks the second approved indication for Adebrelimab in the field of lung cancer. Consequently, it has become the first domestically produced PD-L1 inhibitor in China to receive approval for an NSCLC perioperative indication.

Adebrelimab injection was initially approved for marketing in February 2023. Its previously approved indication is for use in combination with carboplatin and etoposide as a first-line treatment for patients with extensive-stage small cell lung cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment